Alnylam Pharmaceuticals, Inc (ALNY)

Alnylam's stock has been impacted by several events. Strong Q3 2025 financial results, with a 103% increase in net product revenues, led to bullish sentiment. Q4 and full-year 2025 results showed significant revenue growth and GAAP profitability, contributing to a higher stock price. As of March 21, 2026, the stock had increased by 10.18% over the last 12 months, but decreased by 7.14% in the past month. ALNY climbed 4.97% on March 25, 2026, closing at $323.36. Historically, the stock experiences challenges during "Growth & Demand Scare" conditions.

Alnylam Pharmaceuticals anticipates lower TTR revenue growth in the first quarter of 2026 due to international pricing adjustments and seasonal factors. However, they project higher quarterly growth for the remainder of the year, suggesting an overall positive trend despite fluctuations.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on RNA interference (RNAi) therapeutics. They develop medicines by silencing genes that cause diseases. Their portfolio includes AMVUTTRA for hATTR amyloidosis with polyneuropathy and ATTR cardiomyopathy, ONPATTRO for the polyneuropathy of hATTR amyloidosis, GIVLAARI for acute hepatic porphyria (AHP), OXLUMO for Primary Hyperoxaluria Type 1 (PH1), and Leqvio for hypercholesterolemia. The company's R&D targets genetically validated genes and utilizes N-acetylgalactosamine (GalNAc) conjugates or lipid nanoparticles (LNPs) for siRNA delivery, primarily to the liver, while also refining approaches for delivery to the heart, skeletal muscle, and adipose tissue.

Alnylam Pharmaceuticals' headquarters and research labs are in Cambridge, Massachusetts, with manufacturing facilities in Cambridge and Norton, Massachusetts. They have European business offices in Maidenhead, UK, and Zug, Switzerland, with satellite offices in Munich, Amsterdam, Vienna, Paris, Milan, Madrid, and Stockholm. Other international offices include Tokyo, Sao Paulo, and Mississauga. Alnylam employs over 2,100 people worldwide as of 2025, with offices in 20 other countries.

Alnylam Pharmaceuticals has a strong brand reputation as a leader in RNAi therapeutics. The company is recognized for translating science into innovative medicines and its "Alnylam P5x25" strategy. The approval of AMVUTTRA for ATTR-CM in the U.S. in 2025 significantly bolstered Alnylam's reputation, driving revenue growth and profitability. The company's focus on patient access and support programs also contributes positively to its brand image.

Alnylam Pharmaceuticals has significant institutional ownership, accounting for 86.46% of shares. Major institutional owners include Capital World Investors, Fmr Llc, Vanguard Group Inc, BlackRock, Inc., Capital Research Global Investors, JPMorgan Chase & Co, State Street Corp, Geode Capital Management, Llc, Baillie Gifford & Co, and Norges Bank. Individual ownership stands at 0.45%.